The Time Has Come for Targeted Therapies for AML: Lights and Shadows

Acute myeloid leukemia (AML) is a complex disease characterized by genetic and clinical heterogeneity and high mortality. After 40 years during which the standard of care for patients evolved very little, the therapeutic landscape has recently seen rapid changes, with the approval of eight new drugs...

Descripción completa

Detalles Bibliográficos
Autores principales: Fiorentini, Alessandro, Capelli, Debora, Saraceni, Francesco, Menotti, Diego, Poloni, Antonella, Olivieri, Attilio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359996/
https://www.ncbi.nlm.nih.gov/pubmed/32700072
http://dx.doi.org/10.1007/s40487-019-00108-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359996/
https://www.ncbi.nlm.nih.gov/pubmed/32700072
http://dx.doi.org/10.1007/s40487-019-00108-x

Ejemplares similares